GlassScriptPhysician profile
Patricia B Nee
NPI 1578606448
$4,065.86
in general payments reported to CMS, 2019-2025
36 companies · $897 in 2025
The $897 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $188 · 2021: $32.53 · 2022: $643 · 2023: $885 · 2024: $1,280 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,061.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.43 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $546.86 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $323.31 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $252.34 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $228.47 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.47 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $203.98 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.19 | 2023-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $138.84 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bausch Health US, LLC | $117.50 | 2022-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $96.22 | 2022-2025 | Trintellix |
| Abbott Laboratories | $86.90 | 2020-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $75.65 | 2020-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $75.45 | 2024-2025 | Zoryve |
| Amarin Pharma, INC. | $61.53 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $60.89 | 2023 | Quviviq |
| Almatica Pharma LLC | $46.61 | 2023-2024 | Loreev Xr, Gralise |
| Currax Pharmaceuticals LLC | $44.51 | 2023-2024 | Contrave |
| Sanofi Pasteur INC. | $42.35 | 2019-2023 | |
| Axsome Therapeutics, INC. | $34.96 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $33.84 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $33.38 | 2024-2025 | Capvaxive |
| Genzyme Corporation | $20.83 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.12 | 2025 | Rexulti |
| Verona Pharma, INC. | $18.09 | 2025 | Ohtuvayre |
| Ibsa Pharma INC. | $17.71 | 2025 | Licart, Flector, Tirosint |
| Daiichi Sankyo INC. | $16.80 | 2023 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.39 | 2025 | Caplyta |
| Vbi Vaccine (Delaware) INC. | $16.30 | 2022 | |
| Biogen, INC. | $15.10 | 2024 | Skyclarys, Spinraza |
| Amgen INC. | $14.63 | 2023 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $14.52 | 2025 | Gemtesa |
| Pfizer INC. | $14.43 | 2022 | |
| Allergan, INC. | $11.66 | 2020 | |
| Adlon Therapeutics L.P. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Nee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.